Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer

被引：96
作者：
Freimund, Alison E. [1 ,2 ]
Beach, Jessica A. [1 ]
Christie, Elizabeth L. [1 ,2 ]
Bowtell, David D. L. [1 ,2 ]
机构：
[1] Peter MacCallum Canc Ctr, Canc Res Div, 305 Grattan St, Melbourne, Vic 3000, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic 3010, Australia
来源：
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 2018年 / 32卷 / 06期
关键词：
Ovarian cancer; Primary resistance; Acquired resistance; Chemotherapy; Drug resistance mechanisms; HOMOLOGOUS RECOMBINATION; PARP INHIBITORS; PHASE-II; MULTIDRUG-RESISTANCE; GENE AMPLIFICATION; CELL CARCINOMA; POOR SURVIVAL; PLATINUM; CHEMOTHERAPY; EXPRESSION;
D O I：
10.1016/j.hoc.2018.07.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Resistance in ovarian cancer is driven by a range of mechanisms, some of which are therapy specific whereas others confer multidrug resistance. This review outlines our current understanding of the heterogeneous mechanisms of both primary and acquired drug resistance in high-grade serous ovarian cancer with a focus on the most common therapeutics, including platinum and taxanes. Current therapeutic strategies for overcoming resistance, including the use of non-P-glycoprotein substrate therapies, are outlined, with an emphasis on the importance of developing resistance biomarkers to guide future therapy approaches and improve patient outcomes.
引用
收藏
页码：983 / +
页数：15
相关论文
共 80 条
[11]   53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks [J].
Bunting, Samuel F. ;
Callen, Elsa ;
Wong, Nancy ;
Chen, Hua-Tang ;
Polato, Federica ;
Gunn, Amanda ;
Bothmer, Anne ;
Feldhahn, Niklas ;
Fernandez-Capetillo, Oscar ;
Cao, Liu ;
Xu, Xiaoling ;
Deng, Chu-Xia ;
Finkel, Toren ;
Nussenzweig, Michel ;
Stark, Jeremy M. ;
Nussenzweig, Andre .
CELL, 2010, 141 (02) :243-254
[12]   Expression of the Major Fas Family and Bcl-2 Family of Proteins in Epithelial Ovarian Cancer (EOC) and Their Correlation to Chemotherapeutic Response and Outcome [J].
Chaudhry, Parvesh ;
Srinivasan, Radhika ;
Patel, Firuza D. .
ONCOLOGY RESEARCH, 2010, 18 (11-12) :549-559
[13]   Molecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance [J].
Chen, Kevin G. ;
Sikic, Branimir I. .
CLINICAL CANCER RESEARCH, 2012, 18 (07) :1863-1869
[14]   Cisplatin Resistant Spheroids Model Clinically Relevant Survival Mechanisms in Ovarian Tumors [J].
Chowanadisai, Winyoo ;
Messerli, Shanta M. ;
Miller, Daniel H. ;
Medina, Jamie E. ;
Hamilton, Joshua W. ;
Messerli, Mark A. ;
Brodsky, Alexander S. .
PLOS ONE, 2016, 11 (03)
[15]   Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999 [J].
Cripe, Larry D. ;
Uno, Hajime ;
Paietta, Elisabeth M. ;
Litzow, Mark R. ;
Ketterling, Rhett P. ;
Bennett, John M. ;
Rowe, Jacob M. ;
Lazarus, Hillard M. ;
Luger, Selina ;
Tallman, Martin S. .
BLOOD, 2010, 116 (20) :4077-4085
[16]   ERCC1 AND ERCC2 EXPRESSION IN MALIGNANT-TISSUES FROM OVARIAN-CANCER PATIENTS [J].
DABHOLKAR, M ;
BOSTICKBRUTON, F ;
WEBER, C ;
BOHR, VA ;
EGWUAGU, C ;
REED, E .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (19) :1512-1517
[17]   Clear cell carcinoma of the ovary: A review of the literature [J].
del Carmen, Marcela G. ;
Birrer, Michael ;
Schorge, John O. .
GYNECOLOGIC ONCOLOGY, 2012, 126 (03) :481-490
[18]   TCEB2 confers resistance to VEGF-targeted therapy in ovarian cancer [J].
Deng, Zhuo ;
Zhou, Jiancheng ;
Han, Xi ;
Li, Xu .
ONCOLOGY REPORTS, 2016, 35 (01) :359-365
[19]  
Di Nicolantonio F, 2004, ANTI-CANCER DRUG, V15, P861
[20]   Resistance to therapy caused by intragenic deletion in BRCA2 [J].
Edwards, Stacey L. ;
Brough, Rachel ;
Lord, Christopher J. ;
Natrajan, Rachael ;
Vatcheva, Radost ;
Levine, Douglas A. ;
Boyd, Jeff ;
Reis-Filho, Jorge S. ;
Ashworth, Alan .
NATURE, 2008, 451 (7182) :1111-U8
12345678